Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | isoleucyl-tRNA synthetase, putative | 0.0025 | 0.0324 | 0.5 |
Leishmania major | isoleucyl-tRNA synthetase, putative | 0.0025 | 0.0324 | 0.5 |
Mycobacterium tuberculosis | Probable formamidopyrimidine-DNA glycosylase Fpg (FAPY-DNA glycosylase) | 0.009 | 0.2627 | 1 |
Giardia lamblia | Isoleucyl-tRNA synthetase | 0.0025 | 0.0324 | 0.5 |
Echinococcus multilocularis | isoleucyl tRNA synthetase, cytoplasmic | 0.0025 | 0.0324 | 0.0197 |
Chlamydia trachomatis | isoleucine--tRNA ligase | 0.0025 | 0.0324 | 0.5 |
Brugia malayi | isoleucyl-tRNA synthetase | 0.0025 | 0.0324 | 0.5 |
Echinococcus multilocularis | X box binding protein 1 | 0.0295 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA glycosylase | 0.009 | 0.2627 | 1 |
Mycobacterium ulcerans | formamidopyrimidine-DNA glycosylase | 0.009 | 0.2627 | 1 |
Mycobacterium leprae | Probable formamidopyrimidine-DNA glycosylase Fpg (FAPY-DNA GLYCOSYLASE) | 0.009 | 0.2627 | 1 |
Echinococcus granulosus | isoleucyl tRNA synthetase, cytoplasmic | 0.0025 | 0.0324 | 0.0197 |
Plasmodium falciparum | isoleucine--tRNA ligase, putative | 0.0099 | 0.295 | 1 |
Brugia malayi | isoleucyl-tRNA synthetase family protein | 0.0025 | 0.0324 | 0.5 |
Toxoplasma gondii | isoleucyl-tRNA synthetase family protein | 0.0025 | 0.0324 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0295 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0324 | 1 |
Onchocerca volvulus | 0.002 | 0.0129 | 0.5 | |
Trichomonas vaginalis | isoleucyl tRNA synthetase, putative | 0.0025 | 0.0324 | 0.5 |
Loa Loa (eye worm) | isoleucyl-tRNA synthetase | 0.0025 | 0.0324 | 1 |
Plasmodium vivax | isoleucine--tRNA ligase, putative | 0.0025 | 0.0324 | 0.5 |
Trypanosoma cruzi | isoleucyl-tRNA synthetase, putative | 0.0025 | 0.0324 | 0.5 |
Mycobacterium ulcerans | formamidopyrimidine-DNA glycosylase | 0.009 | 0.2627 | 1 |
Trypanosoma brucei | isoleucyl-tRNA synthetase, putative | 0.0025 | 0.0324 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | formamidopyrimidine-DNA glycosylase | 0.009 | 0.2627 | 1 |
Treponema pallidum | isoleucyl-tRNA synthetase | 0.0025 | 0.0324 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 18.25 % | Induction of apoptosis in human K562 cells assessed as accumulation at subG1 phase at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 18.25 % | Induction of apoptosis in human K562 cells assessed as accumulation at subG1 phase at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 26.7 % | Cell cycle arrest in human K562 cells by accumulation at G0/G1 phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 26.7 % | Cell cycle arrest in human K562 cells by accumulation at G0/G1 phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 36.2 % | Cell cycle arrest in human K562 cells by accumulation at G2/M phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 36.2 % | Cell cycle arrest in human K562 cells by accumulation at G2/M phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 37.1 % | Cell cycle arrest in human K562 cells by accumulation at S phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 37.1 % | Cell cycle arrest in human K562 cells by accumulation at S phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
GI50 (functional) | = 13.6 uM | Cytotoxicity against human HCT15 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 13.6 uM | Cytotoxicity against human HCT15 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 16.1 uM | Cytotoxicity against human MDA-MB-435 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 16.1 uM | Cytotoxicity against human MDA-MB-435 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 16.7 uM | Cytotoxicity against human LOX IMVI cells | ChEMBL. | 17485212 |
GI50 (functional) | = 16.7 uM | Cytotoxicity against human LOX IMVI cells | ChEMBL. | 17485212 |
GI50 (functional) | = 17.4 uM | Cytotoxicity against human DU145 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 17.4 uM | Cytotoxicity against human DU145 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 19.2 uM | Cytotoxicity against human K562 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 19.2 uM | Cytotoxicity against human K562 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 20 uM | Cytotoxicity against human OVCAR3 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 20 uM | Cytotoxicity against human OVCAR3 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 21 uM | Cytotoxicity against human SF295 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 21 uM | Cytotoxicity against human SF295 cells | ChEMBL. | 17485212 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.